Please wait a minute...
European Journal of Gynaecological Oncology  2017, Vol. 38 Issue (4): 560-563    DOI: 10.12892/ejgo3602.2017
Original Research Previous articles | Next articles
Villin immunohistochemical expression in endometrial carcinoma
W. Gomaa1, 2, N. Anfinan3, K. Sait3, H. Sait4, A. Oraif3, M. Al-Ahwal5, J. Al-Maghrabi1, 6, *()
1 Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
2 Department of Pathology, Faculty of Medicine, Minia University, Al Minia, Egypt
3 Department of Obstetrics and Gynecology, Gynecology Oncology Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
4 Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
5 Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
6 Department of Pathology, King Fasial Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
Download:  PDF(609KB)  ( 21 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Introduction: Villin is a highly specialised protein and is expressed in intestinal epithelium. It was detected in colorectal carcinomas and other non-gastrointestinal tumours. The aim of the current study was to investigate the immunohistochemical expression of villin in endometrial carcinoma and normal endometrium. Materials and Methods: Tissue microarray blocks were prepared from 73 archival of endometrial carcinomas obtained from the Department of Pathology at King Abdulaziz University Jeddah, Saudi Arabia. Tissue sections were stained using anti-human villin monoclonal antibody. The extent of immunostaining results were recorded and categorised. Results: Positive immunostaining for villin was observed in 12.3% of endometrial carcinoma and was negative in all non-neoplastic endometrial tissues. Villin staining was observed in the apical surface cytoplasm and nucleus. Villin expression showed no age preference. All positive tumours are of the endometrioid type with no preference to histological grade or stage. Conclusion: In summary, the authors observed the immunostaining in a small number of endometrial carcinomas in the apical border, cytoplasm, and for the first time in nucleus. Endometrial carcinomas should be considered when evaluating patients with villin positive adenocarcinoma of unknown origin. The mechanism and the importance of villin immunostaining and its expression pattern in endometrial carcinoma needs further investigations.
Key words:  Endometrium      Tissue microarray      Immunohistochemistry      Antibody     
Published:  10 August 2017     
*Corresponding Author(s):  J. AL-MAGHRABI     E-mail:  almgrabi@kau.edu.sa

Cite this article: 

W. Gomaa, N. Anfinan, K. Sait, H. Sait, A. Oraif, M. Al-Ahwal, J. Al-Maghrabi. Villin immunohistochemical expression in endometrial carcinoma. European Journal of Gynaecological Oncology, 2017, 38(4): 560-563.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3602.2017     OR     https://ejgo.imrpress.com/EN/Y2017/V38/I4/560

[1] Marcin Jedryka, Agnieszka Chrobak, Anna Chelmonska-Soyta, Daria Fijalkowska, Rafal Matkowski. Decreased expression of estrogen receptors alpha and beta in peripheral blood lymphocytes from the endometrial cancer patients and women with endometriosis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 375-379.
[2] H. Cokmez, A. Yilmaz. Concordance of preoperative and postoperative histological grades in endometrioid type endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 208-213.
[3] Sung-Im Do, Hee-Chul Shin, Hee Sung Kim. Clinical significance of MET receptor protein and mRNA expression in invasive breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 240-245.
[4] Y. S. Lee, J. M. Baek, E. K. Park, C. J. Kim, H. J. Lee, J. O. Kim. Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 65-69.
[5] M.H. Hajeer, A. Al Khader, N.A. Shahin, M.S. Bata. Negative p53 expression and negative high risk HPV in a 26-year-old lady with vulvar keratinizing squamous cell carcinoma: report of a case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 130-133.
[6] R. Tasaka, Y. Hashiguchi, M. Kasai, T. Fukuda, T. Ichimura, T. Yasui, T. Sumi. Secondary small cell carcinoma of the endometrium after concurrent chemoradiotherapy for cervical cancer: a rare case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 142-144.
[7] T. Wada, Y. Hashiguchi, M. Kasai, T. Fukuda, T. Ichimura, T. Yasui, T. Sumi. HMGCR antibody-associated myopathy in patient with endometrial cancer: a rare case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 148-150.
[8] N. K. Šuster, M. Meznaric, N. Škorja, I. Virant-Klun, I. Verdenik, Š. Smrkolj. Cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting and immunohistochemistry: comparison of two techniques[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 948-952.
[9] Yangyang Shi, Yongyun Shi, Dabao Wu. A case of placental site trophoblastic tumor and a retrospective analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1096-1099.
[10] H. Ibrahim, K. Dresser, K. M. Cornejo. Loss of 5-hydroxymethylcytosine (5-hmC) expression in endometrioid type endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 846-848.
[11] A.M. Sindiani, M.S. Alorjani, B.K. Aldaraiseh. Dysgerminoma of the ovary in an adolescent girl associated with a high serum β-human chorionic gonadotropin (β-hCG) level[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 859-861.
[12] S. Kabukcuoglu, B. Hayit. Histopathologic features of advanced stage endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 614-618.
[13] X. Lyu, P. Liu, H. Mao, B. Han, X. Wei. Small cell carcinoma of the endometrium mixed with endometriod adenocarcinoma: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 676-678.
[14] Lan Zhong, Feng Deng, Xingsheng Shu, Zhilan Peng. P53 overexpression predicts unfavorable prognosis of low risk endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 463-467.
[15] H. Matsushita, H. Yabushita, T. Tsuzuki, A. Wakatsuki. Squamous cell carcinoma of the endometrium with contiguous superficial spreading to the vagina, uterine cervix, fallopian tube, and ovary[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 487-489.
No Suggested Reading articles found!